Residual Tumor Cellularity Assessment After Neoadjuvant Therapy

Residual Tumor Cellularity (RTC) assessment after neoadjuvant therapy is essential for evaluating treatment response and guiding further clinical decisions in breast cancer care. We intend to develop a comprehensive and practical system to assess tumor cellularity from H&E-stained whole slide images. This project intends to leverage multimodal AI to support precise prognostic evaluation, enable timely treatment adjustments, and facilitate large-scale, standardized pathology analysis in both high- and low-resource settings.